Introducing our hiEX™ Research iPSC Exosomes
For powering next-generation regenerative medicine research
June 24, 2025 11:00 AM PST
Meet our hiEX™ Research iPSC Exosomes, a new research-use-only product designed to enable scientists to explore the therapeutic potential of iPSC-derived exosomes in areas such as wound healing, aging, and nerve regeneration
Isolated from a single, well-characterized induced pluripotent stem cell (iPSC) line, hiEX™ Research iPSC Exosomes offer a consistent and scalable alternative to donor-derived exosomes. While available off-the-shelf in PBS, they can be custom-formulated and even engineered, thanks to the presence of our patented TARGATT™ large knock-in technology in the source cell line, turning hiEX™ Research iPSC Exosomes into a versatile platform for discovery and translational research.
“Our hiEX™ iPSC Exosomes give researchers a dependable and well-defined starting point for exploring the possibilities of these cell-free tools in regenerative medicine.”
CEO
By combining the scalability of iPSCs with rigorous quality control and the potential for fast gene knock-in into the parent line, hiEX™ Research iPSC Exosomes enable researchers to pursue deeper insights into regenerative mechanisms and lay the groundwork for therapeutic innovations.
About Applied StemCell
Founded in 2008 to provide industry and academic researchers with the ability to leverage the power of induced pluripotent stem cells (iPSC) and gene editing, Applied StemCell continues to use our innovative technologies to power the discovery and development of advanced therapeutics. Our products and services enable the full spectrum of basic research to GMP manufacturing—including disease modeling, iPSC services, mammalian cell line engineering, and nonclinical and pre-IND studies—and our patented technologies ensure a clear IP path to commercialization.
Media Contact
Pia Abola
Director of Marketing
pia.abola@appliedstemcell.com
+1 (408) 457-1312
